{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:37:34Z","timestamp":1768567054818,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cld.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T07:34:09Z","timestamp":1726817649000},"page":"135-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Chronic Liver Disease in Patients with Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"29","author":[{"given":"Zachary H.","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis K.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261619","article-title":"Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma","volume":"17","author":"Kondo","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cld.2024.08.004_bib2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome. 2021 practice guidance by AASLD","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotemic patients with cirrhosis: results of an open randomized clinical trial","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"34","author":"Sort","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2024.08.004_bib5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cgh.2021.07.018","article-title":"Advancing Liver Therapeutics Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension","volume":"20","author":"Boike","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.08.004_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and mortality among patients on the liver transplant waiting list","volume":"359","author":"Kim","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2024.08.004_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2036.2011.04746.x","article-title":"Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: an updated Cochrane review","volume":"34","author":"Chavez-Tapra","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2024.08.004_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII Faculty. Baveno VII: renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the AASLD","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2024.08.004_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"issue":"10181","key":"10.1016\/j.cld.2024.08.004_bib12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"B-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled multicenter trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cld.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/liv.15458","article-title":"A\u00a0history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC","volume":"42","author":"Larrey","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2024.08.004_bib14","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"19","author":"Gordan","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12876-023-03047-0","article-title":"Risks and benefits of TIPS in HCC and other malignancies: a literature review","volume":"23","author":"Fichtl","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2024.08.004_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"RIfaximin treatment for hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2024.08.004_bib17","first-page":"CD003044","article-title":"Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"4","author":"Gluud","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL clinical practice guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.08.004_bib19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the AASLD","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2024.08.004_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2024.08.004_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3348\/kjr.2022.0395","article-title":"Complications related to transarterial treatment of hepatocellular carcinoma: a comprehensive review","volume":"24","author":"Lee","year":"2023","journal-title":"Korean J Radiol"},{"issue":"89","key":"10.1016\/j.cld.2024.08.004_bib22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.bjc.6601329","article-title":"Postchemoembolisation syndrome \u2013 tumour necrosis or hepatocyte injury?","author":"Wigmore","year":"2003","journal-title":"Brit J Canc"},{"issue":"3","key":"10.1016\/j.cld.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/RCT.0b013e3181caaea3","article-title":"Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome","volume":"34","author":"Wagnetz","year":"2010","journal-title":"J\u00a0Comput Assist Tomogr"},{"key":"10.1016\/j.cld.2024.08.004_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2024.08.004_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/lt.25354","article-title":"New systemic treatments in advanced hpatocellular carcinoma","volume":"25","author":"Sanduzzi-Zamparelli","year":"2019","journal-title":"Liv Transpl"},{"key":"10.1016\/j.cld.2024.08.004_bib26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2024.08.004_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CEJ.0000000000000428","article-title":"Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. [Review]","volume":"27","author":"Baecker","year":"2018","journal-title":"Eur J Cancer Prev"},{"issue":"12","key":"10.1016\/j.cld.2024.08.004_bib28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.cld.2024.08.004_bib29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cld.2021.06.006","article-title":"Controversies in the management of hepatitis B: hepatocellular carcinoma","volume":"25","author":"Roberts","year":"2021","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2024.08.004_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2024.08.004_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.08.004_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2024.08.004_bib33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2024.08.004_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148493","article-title":"Risk factors and post-resection independent predictive score for the recurrence of hepatitis B-related hepatocellular carcinoma","volume":"11","author":"Hung","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cld.2024.08.004_bib35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.cld.2024.08.004_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11684-021-0848-3","article-title":"Adjuvant treatment strategy after curative resection for hepatocellular carcinoma","volume":"15","author":"Zhang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.cld.2024.08.004_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000324197","article-title":"High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence","volume":"84","author":"Li","year":"2011","journal-title":"Digestion"},{"key":"10.1016\/j.cld.2024.08.004_bib38","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10620-018-5252-8","article-title":"Efficacy of nucleoside analogs for chronic hepatitis B virus-related hepatocellular carcinoma after curative treatment: a meta-analysis","volume":"63","author":"Zhang","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2024.08.004_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122041","article-title":"Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma","volume":"10","author":"Jang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2024.08.004_bib40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ejso.2013.03.020","article-title":"Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma:a retrospective study","volume":"39","author":"Dan","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.cld.2024.08.004_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000342913","article-title":"Hepatitis B virus reactivation during treatment with multi-tyrosine kinase inhibitor for hepatocellular carcinoma","volume":"5","author":"Shiba","year":"2012","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cld.2024.08.004_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201316","article-title":"Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: a multicenter study","volume":"13","author":"Jun","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2024.08.004_bib43","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cld.2024.08.004_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cld.2024.08.004_bib45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.cld.2024.08.004_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.13659","article-title":"The impact of treatment of hepatitis C with DAAs on the occurrence of HCCC","volume":"38","author":"Roche","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2024.08.004_bib47","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0000000000001152","article-title":"Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact","volume":"30","author":"Hasssan","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5Pt1","key":"10.1016\/j.cld.2024.08.004_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cld.2024.08.004_bib49","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2024.08.004_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233212","article-title":"Impact of direct-acting antiviral therapy for hepatitis C\u2013related hepatocellular carcinoma","volume":"15","author":"Lin","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2024.08.004_bib51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.hpb.2020.07.012","article-title":"Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study","volume":"23","author":"Turgeon","year":"2021","journal-title":"HPB"},{"key":"10.1016\/j.cld.2024.08.004_bib52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2024.08.004_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.08.004_bib54","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2169\/internalmedicine.8456-21","article-title":"The impact of antiviral therapy for hepatitis C virus on the survival of patients after hepatocellular carcinoma treatment","volume":"61","author":"Mori","year":"2022","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.cld.2024.08.004_bib55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2008.11.001","article-title":"Hepatic iron overload and hepatocellular carcinoma","volume":"286","author":"Kew","year":"2009","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.cld.2024.08.004_bib56","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.4254\/wjh.v14.i9.1804","article-title":"Hereditary hemochromatosis: temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer \u2013 nationwide population-based study","volume":"14","author":"Haider","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2024.08.004_bib57","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/COC.0000000000000583","article-title":"Modern outcomes following treatment of hepatocellular carcinoma in hereditary hemochromatosis","volume":"42","author":"McPhail","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cld.2024.08.004_bib58","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.32355","article-title":"Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: a population-based analysis","volume":"76","author":"Han","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2024.08.004_bib59","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(21)00279-5","article-title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study","volume":"22","author":"Rumgay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cld.2024.08.004_bib60","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2024.08.004_bib61","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2024.08.004_bib62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1940-6207.CAPR-20-0549","article-title":"Adiposity, adulthood weight change, and risk of incident hepatocellular carcinoma","volume":"14","author":"Simon","year":"2021","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.cld.2024.08.004_bib63","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.dld.2021.12.002","article-title":"Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk","volume":"54","author":"Nasereldin","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2024.08.004_bib64","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:17:08Z","timestamp":1755011828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326124000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1089326124000722"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.08.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Chronic Liver Disease in Patients with Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}